Meeting Brochure and registration form      SMDM Homepage

Sunday, 23 October 2005
23

MODELING TOTAL ANNUAL COST OF MONTELUKAST IN THE TREATMENT OF ASTHMA WITH CONCOMITANT ALLERGIC RHINITIS IN FRANCE

Sabine Gaugris, MSc., Rutgers University, Piscataway, NJ and Vasilisa Sazonov Kocevar, PhD, Merck & Co. Inc., Whitehouse Station, NJ.

Purpose. Evaluate total annual costs [TAC] associated with management of asthma and comorbid allergic rhinitis [A+AR] among patients treated with either montelukast [MON] or long acting beta agonists [LABA] added to inhaled corticosteroids [ICS] in France. Methods. A cost minimization analysis based model using 3rd party payer's perspective was developed. TAC per patient included asthma controller acquisition cost [ACAC], A+AR related concomitant drug cost [AAR-COST] (incl. allergy, rescue/acute and other asthma medications) and asthma-related medical resource use [A-MRU] cost (incl. unscheduled physician visits, ER visits, hospitalizations). ACAC were calculated using published daily cost, observed and published dosing and compliance. The latter included average prescription [Rx] duration and % of compliant patients. AAR-COST were derived from a French observational study and A-MRU cost from a randomized clinical trial along with published unit costs. A deterministic sensitivity analysis (SA) for ACAC varied the average Rx duration [range 30-100% including the observed rate] and dosing (indicated-Vidal, observed-IMS). AAR-COST, A-MRU and TAC underwent a probabilistic sensitivity analysis using 2nd order Monte Carlo simulation (500 iterations). Results. Base case. Treatment of A+AR patients with ICS+MON vs ICS+LABA results in similar AAR-COST [€137 for ICS+MON vs. €137 for ICS+LABA] and similar A-MRU cost [€152 vs. €132]. These two costs combined were €288 for ICS+MON vs. €269 for ICS+LABA. ACAC was €120 for ICS+MON vs. €121 for ICS+LABA using observed compliance rate, and €306 vs. €322 with 100% compliance. TAC per patient was €409/€594 in the ICS+MON group and at €390/€592 in the ICS+LABA group for observed/100% compliance rates respectively. None of the estimates were statistically different between groups. Conclusion. Total annual cost per patient with asthma+AR is similar among patients treated with ICS+MON compared to patients using ICS+LABA. Multiple sensitivity analyses demonstrate that these conclusions are robust.

See more of Poster Session II
See more of The 27th Annual Meeting of the Society for Medical Decision Making (October 21-24, 2005)